

# Synthesis of New Tetracyclic Fused Imidazole Derivatives

M. Bakavoli<sup>a,c,\*</sup>, F. Pirouzi<sup>a</sup>, M. Nikpour<sup>b</sup>, F. Bamoharram<sup>a</sup> and A. Davoodnia<sup>a</sup>

a: Department of Chemistry, School of Sciences, Islamic Azad University, Mashhad Branch, Mashhad, Iran. b: Department of Chemistry, School of Sciences, Islamic Azad University, Ahvaz Branch, Ahvaz 61349-68875, Iran. c: Department of Chemistry, School of Sciences, Ferdowsi University, Mashhad 91775-1436, Iran.  
email:mbakavoli@yahoo.com

## Abstract


Reaction of 2-(4,5-dihydro-1H-imidazol-2-yl)thieno[2,3-b]pyridine-3-amine with monofunctional and bifunctional electrophilic reagents gave new imidazo[1,2-c]pyrido[3',2',4,5]thieno[2,3-e]pyrimidine derivatives and derivatives of the novel heterocyclic ring system, imidazo[1,2-d]pyrido[3',2',4,5]thieno[2,3-f][1,4]diazepine respectively.

## Introduction

Imidazole is a privileged structure that occurs in a number of pharmacologically significant molecules. Analogues have shown utility as GABA brain receptor ligands (1), anti-allergy (2), gastric H<sup>+</sup>, K<sup>+</sup> ATPase inhibitor (3), TNF- $\alpha$  production inhibitor (4), antimicrobial and fungicidal (5), carcinoma cells growth inhibitor (6), PAF receptor antagonists (7), immunosuppressive agents (8) and benzodiazepine receptor ligands (9). In view of these facts and due to our interest in the synthesis of fused heterocyclic compounds of biological significance, it seems worthwhile to synthesize new tetracyclic fused imidazo derivatives with eventful perspectives for examination of their possible biological performance.

## Results and Discussion


Our synthesis started from 2-(4,5-dihydro-1H-imidazo-2-yl)thieno[2,3-b]pyridine-3-amine **1**, which was prepared according to a published method (10). Reaction of this compound with chloroacetyl chloride and oxalyl chloride gave 2,7-Dihydro-3H-imidazo[1,2-d]pyrido[3',2':4,5]thieno[2,3-f][1,4]diazepin-6(5H)-one **2a** and 2,7-Dihydro-3H-imidazo[1,2-d]pyrido[3',2':4,5]thieno[2,3-f][1,4]diazepin-5,6-dione **2b** respectively as shown in Scheme 1.



Scheme 1.

The IR spectra exhibit the stretching vibration bands at 1600 & 3200 cm<sup>-1</sup> due to C=O and NH absorption. More proofs came from <sup>1</sup>H NMR spectra, which show a signal at

$\delta$ , 8.05 and 10 ppm for compounds **2a,b** due their NH moiety and methylene group of compound **2a** observed as a singlet on  $\delta$ , 3.5 ppm. Condensation of precursor with cyanogenbromide, carbondisulfide and 4- chlorobenzaldehyde gave the imidazo[1, 2-*c*]pyrido[3', 2', 4, 5]thieno[2, 3-*e*]pyrimidine derivatives **3a-c** respectively as shown in **Scheme 2**.



**Scheme 2.**

The IR spectra exhibit the stretching vibration bands at 3300&3400  $\text{cm}^{-1}$  due to  $\text{NH}_2$  absorption for compound **3a** and a band around 3200  $\text{cm}^{-1}$  for NH moiety of compounds **3b,c**.  $^1\text{H}$ NMR spectra of compounds **3a-c** showed the shift of two methylene groups of imidazole ring to downfield in comparison with their precursor and confirmed the formation of pyrimidine nucleus. Mass spectra of all the above compounds truly showed their molecular ions. For example the molecular ions of **3c** ( $M: M+2$ ) was observed at 340 (35%), 342 (11%) corresponding to the molecular formula  $\text{C}_{17}\text{H}_{13}\text{ClN}_4\text{S}$ .

### Experimental

The melting points were recorded on an Electrothermal type 9100 melting point apparatus. The IR spectra were obtained on a 4300 Shimadzu Spectrometer. The  $^1\text{H}$ NMR (100 MHz) spectra were recorded on a Bruker AC 100 spectrometer. The mass spectra were scanned on a Varian Mat CH-7 instrument at 70 eV. Elemental analysis was obtained on a Thermo Finnigan Flash EA microanalyzer.

#### 2,7- Dihydro- 3H- imidazo[1,2-*d*]pyrido[3',2':4,5]thieno[2,3-*f*][1,4]diazepin-6(5H)-one (**2a**)

Chloroacetylchloride (0.25ml) was dropwisely added to 2- (4,5- dihydro- 1H- imidazol- 2- yl)thieno[2, 3- *b*]pyridine- 3- amine (**1**) (0.646 gr, 3mmol) in chloroform (15ml) and stirred for 12 hours. The precipitate was filtered off and crystallized from chloroform as orange powder (85% yield, mp 218  $^{\circ}\text{C}$ ).

IR: 3200  $\text{cm}^{-1}$  (NH), 1550  $\text{cm}^{-1}$  (C=O),  $^1\text{H}$ NMR: (  $\text{d}^6$ -DMSO)  $\delta$ , 2.8-3.3 (m, 4H, 2 $\text{CH}_2$ ), 3.5 (s, 2H,  $\text{CH}_2$ ), 7.45 (dd, 1H, CH), 8.05 (br, 1H, NH), 8.5 (dd, 1H, CH), 8.63

(dd, 1H, CH); ms: m/z, 258. *Anal.* Calcd. for C<sub>12</sub>H<sub>10</sub>N<sub>4</sub>OS: C, 55.80; H, 3.90; N, 21.69; S, 12.41. Found : C, 60.07; H, 3.65; N, 21.52; S, 12.20.

**2,7- Dihydro- 3H- imidazo[1,2-*d*]pyrido[3',2':4,5]thieno[2,3-*f*][1,4]diazepin-5,6-dione (2b)**

Oxalylchloride (0.25ml) was dropwisely added to 2- (4,5- dihydro- 1H- imidazol- 2-yl)thieno[2, 3- *b*]pyridine- 3- amine (1) (0.646 gr, 3mmol) in chloroform (15ml) and stirred for 12 hours. The precipitate was filtered off and crystallized from ethanole as orange powder (55% yield, mp 253 °C).

IR: 3280 cm<sup>-1</sup> (NH), 1600 cm<sup>-1</sup> (C=O), <sup>1</sup>HNMR: ( d<sup>6</sup>-DMSO) δ, 2.8-3.3 (m, 4H, 2CH<sub>2</sub>), 7.3 (dd, 1H, CH), 7.95 (dd, 1H, CH), 8.65 (dd, 1H, CH), 10 (br, 1H, NH); ms: m/z, 272. *Anal.* Calcd. for C<sub>12</sub>H<sub>8</sub>N<sub>4</sub>O<sub>2</sub>S: C, 52.93; H, 2.96; N, 20.58; S, 11.78. Found : C, 53.12; H, 3.05; N, 20.39; S, 11.50.

**2,3- Dihydroimidazo[1,2-*c*]pyrido[3',2':4,5]thieno[2,3-*e*]pyrimidin-5-amine (3a)**

Cyanogenbromide (0.30gr) was added to 2- (4,5- dihydro- 1H- imidazol- 2-yl)thieno[2, 3- *b*]pyridine- 3- amine (1) (0.646 gr, 3mmol) in chloroform (15ml) and stirred for 24 hours. The precipitate was filtered off and crystallized from chloroform as brown powder (81% yield, mp 283 °C).

IR: 3300 and 3400 cm<sup>-1</sup> (NH<sub>2</sub>), <sup>1</sup>HNMR: ( d<sup>6</sup>-DMSO) δ, 3.3-3.6 (m, 4H, 2CH<sub>2</sub>), 6.5 (br, 2H, NH<sub>2</sub>), 7.3 (dd, 1H, CH), 8.15 (dd, 1H, CH), 8.45 (dd, 1H, CH); ms: m/z, 243. *Anal.* Calcd. for C<sub>11</sub>H<sub>9</sub>N<sub>5</sub>S: C, 54.31; H, 3.73; N, 28.79; S, 13.18. Found : C, 54.50; H, 3.65; N, 28.52; S, 12.96.

**2,6-Dihydroimidazo[1,2-*c*]pyrido[3',2':4,5]thieno[2,3-*e*]pyrimidin-5(3H)-thione (3b)**

Carbondisulfide (2ml) was added to 2- (4,5- dihydro- 1H- imidazol- 2- yl)thieno[2, 3- *b*]pyridine- 3- amine (1) (0.646 gr, 3mmol) in dimethylformamide (10ml) and refluxed for 12 hours. The reaction mixture was added to water (10ml) and then precipitate was filtered off and crystallized from ethanole as orange powder (61% yield, mp 220 °C).

IR: 3200 cm<sup>-1</sup> (NH), <sup>1</sup>HNMR: ( d<sup>6</sup>-DMSO) δ, 4 (m, 4H, 2CH<sub>2</sub>), 7.65 (dd, 1H, CH), 8.8 (dd, 1H, CH), 9 (dd, 1H, CH), 14 (br, 1H, NH); ms: m/z, 260. *Anal.* Calcd. for C<sub>11</sub>H<sub>8</sub>N<sub>4</sub>S<sub>2</sub>: C, 50.75; H, 3.10; N, 21.52; S, 24.63. Found : C, 50.52; H, 3.22; N, 21.72; S, 24.41.

**5-(4-Chlorophenyl-2,3,5,6- tetrahydroimidazo[1,2-*c*]pyrido[3',2':4,5]thieno[2,3-*e*]pyrimidine (3c)**

4- Chlorobenzaldehyde (0.42gr) was added to 2- (4,5- dihydro- 1H- imidazol- 2-yl)thieno[2, 3- *b*]pyridine- 3- amine (1) (0.646 gr, 3mmol) in dimethylformamide (10ml) and refluxed for 12 hours. The reaction mixture was added to water (10ml) and then precipitate was filtered off and crystallized from ethanole as yellow powder (78% yield, mp 335 °C).

IR: 3250 cm<sup>-1</sup> (NH), <sup>1</sup>HNMR: ( d<sup>6</sup>-DMSO) δ, 3.2 (br, 1H, NH), 3.6 (m, 4H, 2CH<sub>2</sub>), 7.5-8.7 (m, 8H, aromatic and benzylic); ms: m/z, 340, 342. *Anal.* Calcd. for C<sub>17</sub>H<sub>13</sub>ClN<sub>4</sub>S: C, 59.91; H, 3.84; N, 16.44; S, 9.41. Found : C, 59.72; H, 3.97; N, 16.25; S, 9.17.

**References**

- (1) (a) A. Thurkauf, A. Hutchison and P. Albaugh, *U. S. US 6, 013, 650* (Cl. 514-267, A61K31/505), 11 Jan 2000, US Appl. 845, 326, 25 Apr 1997; 19 pp [C. A. **132**, 64269w]. (b) . Thurkauf, A. Hutchison and P. Albaugh, *U. S. US 5, 212, 310* (Cl. 544- 251, C07D487/04), 18 May 1993, Appl. 810, 684, 19 Dec 1991; 17 pp [C. A. **119**, 180811x].
- (2) F. E. Janssens and J. E. Leenaerts, *PCT Int. Appl. WO 95 02, 600* (Cl. C07D487/04), 26 Jan 1995, EP Appl. 93/202, 154, 13 JuL 1993; 31pp [C. A. **122**, 265374u].
- (3) (a) H. Tanaka, K. Fukuzumi, T. Togawa, K. Banno, T. Ushiro, M. Morii and T. Nakatani, *PCT Int. Appl. WO 96 33, 195* (Cl. C07D471/04), 24 Oct 1996, JP Appl. 95/97, 130, 21 Apr 1995; 145 pp [C. A. **126**, 47222j]. (b) M. Morii, I. Wanajo, H. Suzuki, T. Murata and N. Takeguchi, *Maku*, **25**(6), 324 (2000). (c) N. Sato, N. Suzuki, M. Yamaguchi, N. Yamaguchi and K. Okuma, *Jpn. Kokai Tokyo Koho JP 2001 286, 284* (Cl. C12N15/09), 16 Oct 2001, Appl. 2000/103, 966, 5 Apr 2000; 79 pp [C. A. **135**, 314438x].
- (4) H. Kato, J. Sakaguchi, S. Makoto, T. Izumi and K. Kato, *PCT Int. Appl. WO 00 09, 506* (Cl. C07D471/04), 21 Feb 2000, JP Appl. 1999/216, 125, 30 Jul 1999; 111 pp [C. A. **132**, 180573].
- (5) (a) Khander M. M. Rahman, A. Z. M. Shaifullah Chowdhury, M. M. H. Bhuiyan, M. K. Hossain and M. K. Uddin, *Pak. J. Sci. Ind. Res.*, **46** (2), 95, (2003). (b) A. M. Hussein, F. A. Abu- Shanab and E. A. Ishak, *P hosphorus Sulfur and Silicon and the Related Elements*, **159**, 55 (2000).
- (6) K. L. Seley, P. H. A. Januszczyk, L. Zhang and D. T. Dransfield, *J. Med. Chem.* **43** (25), 4877, (2000).
- (7) W. J. Houlihan, S. H. Cheon, V. A. Parrino, D. A. Handley and D. A. Larson, *J. Med. Chem.*, **36** (21), 3098 (1993).
- (8) (a)F. Suzuki, K. Miwa, T. Kuroda, S. Kitamura and H. Manabe, *PCT Int. Appl. WO 93 12, 116* (Cl. C07D495/14), 24 Jun 1993, JP Appl. 91/329, 154, 12 Dec 1991; 52 pp [C. A. **120**, 134467n]. (b) D. M. Goldstein, S. B. Hwang, R. T. Scannel and T. Y. Shen, *PCT Int. Appl. WO 94 04, 537* (Cl. C07D495/04), 03 Mar 1994, US Appl. 933, 395, 20 Aug 1992; 122 pp [C. A. **120**, 315814u].
- (9) (a)R. Borer, W. Gassner, M. Gerecke and E. Kyburz, *Eur. Pat. Appl. EP 519, 307* (Cl. C07D495/22), 23 Dec 1992, CH Appl. 91/1, 791, 17 Jun 1991; 71 pp [C. A. **118**, 213117]. (b) T. Godel, W. Hunkeler, H. Stadler and U. Widmer, *U. S. US 5, 665, 718* (Cl. 514- 220; A61K31/555), 9 Sep 1997, US Appl. 545, 471, 20 Nov 1995; 65 pp [C. A. **127**, 293255c].
- (10) (a)R. Borer, W. Gassner, M. Gerecke and E. Kyburz, *Eur. Pat. Appl. EP 519, 307* (Cl. C07D495/22), 23 Dec 1992, CH Appl. 91/1, 791, 17 Jun 1991; 71 pp [C. A. **118**, 213117]. (b) T. Godel, W. Hunkeler, H. Stadler and U. Widmer, *U. S. US 5, 665, 718* (Cl. 514- 220; A61K31/555), 9 Sep 1997, US Appl. 545, 471, 20 Nov 1995; 65 pp [C. A. **127**, 293255c].

Received on June 30,2008.